SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Angiology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Alpert, M. A.
Right arrow Articles by Mukerji, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alpert, M. A.
Right arrow Articles by Mukerji, V.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
*Genetics Home Reference
Hazardous Substances DB
*OXYGEN
*WARFARIN
Medline Plus Health Information
*Pulmonary Hypertension
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Pharmacotherapy of Chronic Pulmonary Arterial Hypertension: Value and Limitations

Part I: Primary Pulmonary Hypertension

Martin A. Alpert

Division of Cardiology, University of South Alabama, College of Medicine, Mobile, Alabama

Milton D. Concannon

Division of Cardiology, University of South Alabama, College of Medicine, Mobile, Alabama

Basanti Mukerji

Division of Cardiology, University of South Alabama, College of Medicine, Mobile, Alabama

Vaskar Mukerji

Division of Cardiology, University of South Alabama, College of Medicine, Mobile, Alabama

Efforts aimed at assessing pharmacotherapy of pulmonary arterial hypertension (PHT) have largely focused on patients with primary PHT, PHT associated with selected connec tive tissue diseases, and various forms of hypoxic secondary PHT. Part I of this review discusses the value and limitations of a wide variety of vasodilator drugs, oxygen, and warfarin in the treatment of primary PHT with special reference to their effects on pulmonary and systemic hemodynamics, functional capacity, and survival.

Angiology, Vol. 45, No. 8, 667-676 (1994)
DOI: 10.1177/000331979404500801
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement